Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
NCT01764633
|
| gptkbp:designer |
gptkb:clinical_trial
|
| gptkbp:endDate |
2016
|
| gptkbp:foundIn |
evolocumab reduced risk of cardiovascular events
|
| gptkbp:fullName |
Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
|
| https://www.w3.org/2000/01/rdf-schema#label |
FOURIER trial
|
| gptkbp:participants |
27,564
|
| gptkbp:period |
Phase 3
|
| gptkbp:population |
patients with atherosclerotic cardiovascular disease
|
| gptkbp:publicationYear |
2017
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
major adverse cardiovascular events
|
| gptkbp:sponsor |
gptkb:Amgen
|
| gptkbp:startYear |
2013
|
| gptkbp:studiedDrug |
gptkb:evolocumab
|
| gptkbp:bfsParent |
gptkb:evolocumab
|
| gptkbp:bfsLayer |
8
|